Metastatic melanoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Vemurafenib is an oral BRAF kinase inhibitor approved since 2012 for the treatment of patients with unresectable or metastatic melanoma with BRAF mutations.
|
31205066 |
2020 |
Metastatic melanoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Combination therapy with MEK inhibitors improves response rate, progression-free survival, and overall survival in patients with BRAF-mutant metastatic melanoma compared to prior treatment regimens.
|
31790307 |
2020 |
Metastatic melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Current therapies for metastatic melanoma (anti-PD1 and BRAF/MEK inhibitors) can cause drug-induced vitiligo.
|
31532537 |
2020 |
Metastatic melanoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
BRAF- and MEK-targeted therapies are effective in BRAF V600E/K metastatic melanoma and lung cancers; however, responses are short-lived due to emergence of resistance.
|
31744895 |
2020 |
Metastatic melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
We conducted a randomized phase 2 clinical trial of patients with BRAF wild-type metastatic melanoma (up to 2 prior therapies) who received either: (A) AB followed by ipilimumab therapy at progression; or (B) ipilimumab followed by AB treatment at progression.
|
31809326 |
2020 |
Metastatic melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
This phase Ib study (ClinicalTrials.gov, number NCT01656642 ) evaluated the safety and anti-tumor activity of combining atezolizumab (anti-PD-L1) with vemurafenib (BRAF inhibitor), or cobimetinib (MEK inhibitor) + vemurafenib, in patients with BRAF<sup>V600</sup>-mutated metastatic melanoma.
|
31171876 |
2019 |
Metastatic melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
We present the case of a 67 year old Caucasian male that was initially treated with BRAF inhibitors followed by anti-CTLA4 and then anti-PD1 immunotherapy for metastatic melanoma but later developed colorectal cancer.
|
31727009 |
2019 |
Metastatic melanoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
We describe peripheral blood smear, bone marrow morphology, histopathology, immunohistochemistry, including BRAF V600E, and molecular testing results of patients with metastatic melanoma to the bone marrow.
|
31112348 |
2019 |
Metastatic melanoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Efficacy and safety of dabrafenib-trametinib in the treatment of unresectable advanced/metastatic melanoma with BRAF-V600 mutation: A systematic review and network meta-analysis.
|
31664762 |
2019 |
Metastatic melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The combination of BRAF and MEK inhibitors is a standard therapeutic option for patients with metastatic melanoma with BRAF-mutated tumors.
|
30383722 |
2019 |
Metastatic melanoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
In contrast to metastatic melanoma, BRAF inhibition alone or in combination with mitogen-activated protein kinase kinase (MEK) inhibitors has shown little utility in the treatment of BRAF V600E-mutant mCRC.
|
31840683 |
2019 |
Metastatic melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
BRAF and MEK inhibitors (BRAFi and MEKi) are actively used for the treatment of metastatic melanoma in patients with BRAF<sup>V600E</sup> mutation in their tumors.
|
30765391 |
2019 |
Metastatic melanoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
A 75-year-old male developed a swelling in his left inguinal region and was diagnosed with a metastatic melanoma, which was found to harbor a BRAF V600E mutation.
|
31260118 |
2019 |
Metastatic melanoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
BRAF inhibitor therapy may provide profound initial tumor regression in metastatic melanoma with BRAF V600 mutations, but treatment resistance often leads to disease progression.
|
31058079 |
2019 |
Metastatic melanoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
We present the case of a 58-year-old man with a completely regressed metastatic melanoma who developed a second melanoma with concomitant involution of papillomatous nevi under BRAF inhibitors treatment.
|
30944613 |
2019 |
Metastatic melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The BRAF mutation has been identified as a potent target for the treatment of metastatic melanoma and BRAF inhibitors (BRAFi) have demonstrated promising results against melanoma brain metastases (BM).
|
29846702 |
2019 |
Metastatic melanoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Ssecond primary melanomas (SPMs) are new developed primary melanomas occurring in a subset of patients affected by BRAF-mutated metastatic melanoma during treatment with BRAF-inhibitors.
|
31804055 |
2019 |
Metastatic melanoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Here, we report a case of a 45 year-old Caucasian lady with BRAF-V600E mutant metastatic melanoma to the brain who had whole brain radiotherapy followed by two Gamma knife radiosurgery treatments for localized disease progression.
|
30972290 |
2019 |
Metastatic melanoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Patients who have unresectable or metastatic melanoma with a <i>BRAF</i> V600E or V600K mutation have prolonged progression-free survival and overall survival when receiving treatment with BRAF inhibitors plus MEK inhibitors.
|
31166680 |
2019 |
Metastatic melanoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Prospective evaluation of two screening methods for molecular testing of metastatic melanoma: Diagnostic performance of BRAF V600E immunohistochemistry and of a NRAS-BRAF fully automated real-time PCR-based assay.
|
31415669 |
2019 |
Metastatic melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Combined treatment of metastatic melanoma with BRAF and MEK inhibitors has improved survival, but the emergence of resistance represents an important clinical challenge.
|
30833419 |
2019 |
Metastatic melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Dual inhibitor therapy using dabrafenib (a selective oral inhibitor of several mutated forms of BRAF kinase) and trametinib (a reversible inhibitor of MEK1 and MEK2) has been used successfully for treatment of metastatic melanoma, anaplastic thyroid cancer, and other tumor types, but has been reported in only a few patients with primary brain tumors and none with pleomorphic xanthoastrocytoma.
|
31675726 |
2019 |
Metastatic melanoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Patients with stage IV metastatic melanoma and BRAF V600E mutations (n = 11, 31-68 years of age) were included.
|
29324592 |
2019 |
Metastatic melanoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
In order to study the ability of local radiation and anti-PD-1 immunotherapy to induce beneficial anti-tumor immune responses against distant, unirradiated tumors, we used two mouse models of metastatic melanoma in the brain, representing BRAF mutant and non-mutant tumors.
|
30546944 |
2019 |
Metastatic melanoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Drug resistance imposes severe limitations to the efficacy of targeted therapy in BRAF-mutated metastatic melanoma.
|
30254376 |
2019 |